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Background. Autosomal-dominant juvenile hyperuricemia,
gouty arthritis, medullary cysts, and progressive renal insuf-
ficiency are features associated with familial juvenile hyper-
uricemic nephropathy (FJHN), medullary cystic kidney disease
type 1 (MCKD1) and type 2 (MCKD2). MCKD1 has been
mapped to chromosome 1q21. FJHN and MCKD2 have been
mapped to chromosome 16p11.2. FJHN and MCKD2 are al-
lelic, result from uromodulin (UMOD) mutations and the term
uromodulin-associated kidney disease (UAKD) has been pro-
posed for them. Linkage studies also reveal families that do not
show linkage to any of the identified loci. To identify additional
UAKD loci, we analyzed one of these families, with features
suggestive of FJHN.
Methods. Clinical, biochemical, and immunohistochemi-
cal investigations were used for phenotype characterization.
Genotyping, linkage and haplotype analyses were employed
to identify the candidate disease region. Bioinformatics and se-
quencing were used for candidate gene selection and analyses.
Results. We identified a new candidate UAKD locus on chro-
mosome 1q41, bounded by markers D1S3470 and D1S1644. We
analyzed and found no linkage to this region in eight additional
families, who did not map to the previously established loci.
We noted that affected individuals showed, in addition to the
characteristic urate hypoexcretion, significant reductions in uri-
nary excretion of calcium and UMOD. Immunohistochemical
analysis showed that low UMOD excretion resulted from its
reduced expression, which is a different mechanism to intra-
cellular UMOD accumulation observed in cases with UMOD
mutations.
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Conclusion. We have mapped a new candidate UAKD locus
and shown that UAKD may be a consequence of various defects
affecting uromodulin biology.
Familial juvenile hyperuricemic nephropathy (FJHN)
(OMIM 162000) [1, 2] and medullary cystic kidney dis-
eases type 1 (MCKD1) (OMIM 174000) [3] and type 2
(MCKD2) (OMIM 603860) [4] represent a constellation
of autosomal-dominant tubulointerstitial nephropathies,
which are accompanied to a variable extent by hyper-
uricemia, gouty arthritis, medullary cysts, and progres-
sive renal insufficiency. The phenotypic expression of the
diseases is inconsistent, overlaps, and indicates broader
genetic and allelic heterogeneity. Several independent
studies showed linkage of FJHN [5, 6] and MCKD2
[4, 7] to the same genomic region on chromosome 16
p11.2. Recent studies confirmed that FJHN and MCKD2
are allelic disorders resulting from mutations of uromod-
ulin (UMOD) [8–15] and therefore the term uromodulin-
associated kidney disease (UAKD) has been proposed
[8]. MCKD1 was mapped to chromosome 1q21 [16–19],
to which region also an autosomal-dominant form of pro-
gressive renal failure (OMIM 161900) was localized [20,
21]. The above studies further confirmed that both FJHN
[22–25] and MCKD [18, 26] are genetically heteroge-
neous, and that in approximately 40% to 75% of ana-
lyzed families the diseases are likely to be caused by a
gene(s) located outside of the16p11.2. and 1q21 intervals
[11, 12, 25]. To search for other UAKD loci we performed
a genome-wide mapping in a single Belgian family BE1,
which displayed some features of FJHN but in which pre-
vious analyses excluded linkage to FJHN/MCKD2 loci on
chromosome 16p11.2 [25] and to MCKD1 locus on chro-
mosome 1q21 [logarithm of odds (LOD) < −3.8 within
the MCKD1 critical region, analyzing markers D1S534,
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D1S1595, D1S394, and D1S1653]. We identified a new
candidate UAKD gene locus on chromosome 1q41. Hap-
lotype analysis and recombination events detected in af-
fected individuals delimited the candidate disease region
to be bounded by markers D1S3470 and D1S1644. We
also tested and found no linkage to the newly identified
region in eight families from our previous studies that did
not show evidence of linkage to the already established
FJHN/MCKD2 locus on 16p11.2 and MCKD1 locus on
1q21 [18, 23, 25].
Assessing the phenotype, we found that affected in-
dividuals showed, in addition to characteristic urate hy-
poexcretion, significant reduction in urinary excretion of
calcium and UMOD. The immunohistochemical analy-
sis of kidney biopsies showed that low UMOD excre-
tion in family BE1 originated from significantly reduced
UMOD expression. This observation is clearly different
from the characteristic intracellular UMOD accumula-
tion observed in the previously studied cases of FJHN
with UMOD mutations and suggests that various defects
affecting UMOD biology may play a central role in de-
velopment of UAKD.
METHODS
Patients
The investigated families were described and referred
in our previous studies, family C [23], families BE1,
GB1, GB4, GB5, GB6, GB9, GB10, and E2 [25, 27],
and MCKD family 6 [18]. Family BE1 described in this
study was ascertained at the Department of Nephrology
at the University Hospital in Leuven. The family GB6
(for pedigree [25] and for clinical details [27], kindred
7) was ascertained at the Renal Clinics at Guy’s Hos-
pital and Portsmouth Hospital. Medical histories were
obtained as a part of all the patients’ clinical workup by
consultants of the above referred institutions. Clinical and
biochemical investigations essential for the investigation
were explained to the patients prior to performance. Pa-
tient privacy was protected by restricting access to family
names, addresses, and written health records.
Biochemical investigations
Random spot urine samples were collected from avail-
able individuals and were stored until the analyses at
−80◦C. Urine total protein, creatinine, uric acid, magne-
sium, calcium, and phosphate were determined by the
protein (urine) (BioSystems, Costa Brava, Barcelona,
Spain), CREA (Roche, Prague, Czech Republic), UA
Plus (Roche), Mg (Roche), Ca (Roche), and PHOS
(Roche) kits, respectively, on a Hitachi Modular Analyzer
(Roche). Sodium, potassium, and chloride were deter-
mined by ion-selective electrodes. Osmolality was deter-
mined by freezing point technology using FISKE 2400
osmometer.
For quantitative UMOD analysis, thawed urine sam-
ples were diluted (1:250) in tetraethylammonium (TEA)
buffer according to Kobayashi and Fukuoka [28]. UMOD
was quantified by sandwich enzyme-linked immunosor-
bent assay (ELISA) method with antihuman Tamm-
Horsfall protein mouse IgG2b monoclonal antibodies
(Cedarlane, Hornby, Ontario, Canada) as capture an-
tibodies and rabbit antihuman Tamm-Horsfall protein
polyclonal antibodies (Biogenesis, Pool, England) and
goat antirabbit IgG-horseradish peroxidase conjugate as
detection antibodies. As a quantitative standard, UMOD
purified from healthy male urine (according to the
method of Kobayashi and Fukuoka [28]) was used.
For qualitative analysis of urinary UMOD, 250 lL
of urine was concentrated on Microcon YM-30 filters
(Millipore, Bedford, MA, USA) and total protein was
recovered. For analysis of UMOD in sediment, 35 lL
of total urine was centrifuged at 5 000g for 10 min-
utes. About 10 lg of total urinary protein and entire
sediment pellet were dissolved in sodium dodecyl sul-
fate (SDS) sample buffer. Proteins were separated by
SDS-polyacrylamide gel electrophoresis (PAGE) and ei-
ther stained by SYPRO Ruby (Molecular Probes, Eu-
gene, OR, USA), or blotted in a semidry system (Biotec-
Fischer, Reiskirchen, Germany) on polyvinylidine diflu-
oride (PVDF) membranes (Immobilon-P) (Millipore).
Western blot analysis was performed with UMOD mon-
oclonal mouse antibodies (Cedarlane) (primary antibod-
ies) and antimouse Ig antibody conjugated to horseradish
peroxidase (Pierce, Rockford, IL, USA) (secondary an-
tibodies). Chemiluminescent signal was obtained using
SuperSignal West Pico Chemiluminescent Substrate Kit
(Pierce).
Statistical analyses were performed using nonparamet-
ric methods. The Mann-Whitney test was used for the
comparison of continuous variables. The significantly dif-
ferent parameters (disease status characteristics) were
used for discriminant analysis which calculated the pos-
terior probability of an individual being a carrier or not
(Fig. 3). All the statistical analyses were performed using
the software Statistica, version 4.5 (StatSoft, Tulsa, OK,
USA).
Immunohistochemical analysis
Formaldehyde- or ethanol-fixed kidney samples from
a control, a patient with a mutation in UMOD gene,
three individuals from family BE1 (DIII6, DIV3, and
DIV7) and a single proband from family GB6 were an-
alyzed. Immunodetection of UMOD was done on paraf-
fin sections using rabbit anti-Tamm-Horsfall protein an-
tibody (Biogenesis). The paraffin sections were stained
after deparaffination, hydration, and standard blocking
procedures [blocking of endogenous peroxidase with 1%
sodium azide and 0.3% H2O2 for 10 minutes and blocking
with 5% fetal bovine serum (FBS) in phosphate-buffered
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saline (PBS) for 30 minutes, both at room temperature].
The primary antibody was applied diluted 1:800 in 5%
FBS in PBS overnight at 40◦C. Detection of bound pri-
mary antibody was achieved using Dako EnVision+TM
Peroxidase Rabbit Kit (Dako, Glostrup, Denmark) with
3,3′-diaminobenzidine (DAB) as substrate.
Genotype analysis
Genomic DNA was isolated by standard methodol-
ogy. Genotyping was performed with Li-Cor IR2 and
ALFExpress sequencer systems as previously described
[23, 29]. A medium density genome scan of 93 markers
with an average spacing of 30 cM was carried out in 17
individuals from family BE1. The markers were all part
of the Marshfield version 9 screening set. For further fine
mapping on chromosome 1q41 additional markers were
selected and their order and distances between the mark-
ers were obtained from Genethon [30] and Marshfield
databases [31].Genotyping data were screened for errors
using the PEDCHECK program [32]. Mendelian incon-
sistencies were corrected using the original gels or, in
cases where bands could not be unambiguously resolved,
assigned an “unknown” genotype.
Linkage analysis
Two-point and multipoint linkage analyses, along with
determination of the most likely haplotypes, were per-
formed using the Allegro software (deCode Genetics,
Reykjavik, Iceland) [33]. The analyses were carried out
under the assumption of a dominant mode of inheri-
tance with a 0.99 constant, age independent penetrance,
0.01 phenocopy rate, and 0.001 frequency of the disease
allele.
Critical region and candidate genes analyses
Genetic markers were positioned on human genome
contigs by searching actual builds of major human
genome databases–MapViewer (http://www.ncbi.nlm.
nih.gov/), Ensembl (http://www.ensembl.org/), and Hu-
man Genome Working Draft at UCSC, (http://genome.
ucsc.edu/). Individual genes present in delimited critical
region were evaluated according to their expression pro-
files, knowledge or assumption of their function, and anal-
ysis of hypothetical functional domains.
To identify kidney-specific genes and expressed se-
quence tag (EST) clusters, we (1) downloaded from Gene
Expression Omnibus Database (GEO) (http://www.
ncbi.nlm.nih.gov/geo/) data sets of normal human tis-
sue mRNA expression profiling experiments (GDS422-
GDS426), queried kidney expression data sets against
all other available tissues, extracted all genes show-
ing four times higher kidney expression and intersected
resulting expression set with candidate region gene
content; (2) used the Digital Differential Display ap-
proach (http://www.ncbi.nlm.nih.gov/UniGene/) to com-
pare EST sequences derived from kidney cDNA libraries
against EST sequences derived from the pool of nor-
mal human tissues cDNA libraries and intersected re-
sulting set with candidate region gene content; (3) eval-
uated the gene content in a view of recently published
kidney specific gene expression data [34]; (4) focused on
genes that may be connected to UMOD biogenesis [e.g.,
inability of glycosyl-phosphatidylinositol (GPI) anchor
synthesis, proper membrane targeting or proteolytic re-
lease of GPI-anchored membrane proteins; (5) searched
for genes which are known to be involved in hyperten-
sion and/or renal failure; and (6) searched for transcrip-
tion factors and proteins which might regulate UMOD
expression.
Genomic fragments covering promoter region (about
500 bp upstream from the most cDNA 5′end) and all of
the exons and intron-exon boundaries of selected candi-
date genes were polymerase chain reaction (PCR) am-
plified from genomic DNA and sequenced as previously
described [35]. All candidate genes were analyzed in one
proband and one unaffected family member. Genetic
variations were screened against single nucleotide poly-
morphism (SNP) and UNIGENE databases.
RESULTS
Clinical and biochemical findings
The pedigree of the family BE1 is shown in Figure 1. In
this family, the first signs of the disease were mild anemia,
hyperuricemia, and slowly progressive renal insufficiency.
All the patients had small, echogenic kidneys on renal
echography, but renal cysts were not reported. Gout was
not a feature in any of the subjects.
Terminal renal failure developed at 68, 50, and 66 years
of age in DI1, DI3, and DII1, respectively. In the last case
this was treated successfully with renal transplantation.
Individual DII3 (71 years old) showed the main clinical
and biochemical features of the disease. The patient’s cur-
rent clinical status is unknown.
Individual DIII4 (44 years old) is reported as having
anemia, hyperuricemia, small kidneys, and evidence of
renal insufficiency.
Individual DIII6 (43 years old) has been followed
clinically and biochemically for 5 years. Following the
correction of hyperuricemia by allopurinol, the pa-
tient has shown permanently elevated concentration
of plasma creatinine (range 210 to 305 lmol/L) and
urea (range 19 to 22 mmol/L), mild persistent anemia
(hemoglobin range 10.5 to 14 g/dL), and mild intermit-
tent hyperkalemia (range 5.11 to 5.79 mmol/L).The 24-
hour urine collection samples were analyzed six times
and showed reduced creatinine clearance (34 to 37 mL/
min/1.73 m2) with normal concentrations of sodium,
potassium, and chloride. Uric acid excretion was not
measured.
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Fig. 1. Pedigree diagram of the investigated uromodulin-associated kidney disease (UAKD) family linked to 1q41. (A) Black symbols denote
affected individuals and white symbols denote unaffected individuals. Genotyped individuals are underlined. Recombinant markers forming the
haplotype segregating with the disease locus are indicated. (B) Actual allele sizes forming the disease haplotype.
Individual DIV3 (16 years old) was investigated for
the first time at 8 years of age. He showed anemia
(hemoglobin 10 g/dL), hyperuricemia (435 lmol/L), el-
evated concentration of plasma creatinine (80 lmol/L)
and urea (9 mmol/L), and reduced creatinine (51 mL/min/
1.73 m2) and inulin (68 mL/min/1.73 m2) clearance. Hy-
peruricemia was corrected by allopurinol and the patient
has been followed up for 6 years. He has shown persistent
anemia (hemoglobin range 9.5 to 11 g/dL), gradually ris-
ing creatinine plasma concentration (80 to 130 lmol/L)
and urea concentration (9 to 12 mmol/L). Plasma potas-
sium concentrations were within the normal range. The
24-hour urine collection samples showed reduced crea-
tinine clearance (49 to 64 mL/min/1.73 m2) and reduced
uric acid excretion (0.7 to 1 mmol/24 hours, controls 1.25
to 5 mmol/24 hours). Kidney sizes were –2.1 SD bilater-
ally for the corresponding body height.
Individual DIV7 (12 years old) was investigated for the
first time at 4 years of age. The patient showed anemia
(10.1 g of hemoglobin/dL), hyperuricemia (400 lmol/L),
elevated concentration of plasma creatinine (80 lmol/L)
and urea (9.6 mmol/L), and reduced creatinine (60 mL/
min/1.73 m2) and inulin (68 mL/min/1.73 m2) clearance.
Hyperuricemia was corrected by allopurinol and pa-
tient has been followed up for 8 years. The patient
has shown persistent anemia (hemoglobin range 8.8 to
11.9 g/dL), gradually rising creatinine plasma concentra-
tion (80 to 135 lmol/L) and urea concentration (9.6 to
18.5 mmol/L). Mild persistent hyperkalemia (range 5.00
to 5.86 mmol/L) was observed. The 24-hour urine col-
lection samples showed reduced creatinine clearance (46
to 68 mL/min/1.73 m2) and reduced uric acid excretion
(1.2 mmol/24 hours). Kidney sizes were –3.5 SD (right)
and –3.3 SD (left) for the corresponding body height.
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Fig. 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis of urinary uromodulin (UMOD). (A
and C) SYPRO Ruby–labeled proteins in urine and urinary sediment, respectively. (B and D) UMOD detected in the same samples by Western
blot. Lane 1, purified UMOD, 1.5lg; lane 2, female control; lane 3, male control; lane 4, DII5; lane 5, DIV4; lane 6, DIV5; lane 7, DIV7; lane
8, DIV6; lane 9, DII6; lane 10, DIII6; lane 11, DIII4; lane 12, DIV3; lane 13, DIII3; lane 14, control; and lane 15, patient from familial juvenile
hyperuricemic nephropathy (FJHN) family with mutation in UMOD gene. Samples from affected individuals are bold.
Table 1. Urine biochemical parameters measured in individuals from family BEI and controls
Group Mann-Whitney test P values
Healthy Disease Control Disease/ Disease/ Healthy/
Parameter ((N = 6) (N = 4) (N = 77) Healthy Control Control
Age 37 (14–67) 29 (12–44) 36 (22–81) NS NS NS
Creatinine mmol/L 14.0 (5.7–22) 13.4 (7.0–25.0) 9.0 (0.9–24.6) NS NS NS
PO4/creatinine mmol/mmol 1.75 (0.63–2.23) 1.20 (0.70–2.03) 1.96 (0.27–7.3) NS NS NS
UCB/creatinine mg/mmol 10.5 (6.7–16.7) 17.1 (6.3–33.7) 8.5 (0.0–49.5) NS P ≤ 0.05 NS
Potassium/creatinine mmol/mmol 5.65 (1.84–9.67) 3.48 (2.00–4.79) 6.54 (1.61–34.29) NS P ≤ 0.05 NS
Sodium/creatinine mmol/mmol 10.6 (5.1–14.4) 6.2 (2.7–11.7) 13.9 (1.6–49.2) NS P ≤ 0.05 NS
Mg2+/creatinine mmol/mmol 0.26 (0.18–0.42) 0.20 (0.15–0.30) 0.37 (0.14–1.82) NS P ≤ 0.05 NS
Osmolality/creatinine mOsm/mmol 63 (42–88) 39 (20–70) 71 (35–160) NS P ≤ 0.05 NS
Chloride/creatinine mmol/mmol 12.4 (5.3–17.7) 5.6 (1.4–11.5) 17.3 (3.5–49.2) NS P ≤ 0.01 NS
Ca2+/creatinine mmol/mmol 0.38 (0.13–0.58) 0.04 (0.01–0.05) 0.35 (0.04–1.56) P ≤ 0.01 P ≤ 0.001 NS
Uromodulin /creatinine mg/g 30.3 (19.7–53.8) 9.2 (0.0–15.5) 35.7 (7.7–111.0) P ≤ 0.01 P ≤ 0.001 NS
Uric acid/creatinine mmol/mmol 222 (116–362) 49 (17–102) 247 (90–990) P ≤ 0.01 P ≤ 0.001 NS
Values are reported as median (range). P values correspond to the comparison between groups. NS is not significant.
Individuals DIV4, DIV5, and DIV6 are 14, 19, and
17 years old, respectively. They were thoroughly inves-
tigated at the age of 8, 11, and 16 years of age, and 9 and
14 years of age, respectively. They showed no biochemi-
cal abnormality in any of above-mentioned parameters.
Their clinical status remains stable up to now, with normal
renal function.
To assess the most current biochemical status of the in-
dividuals enrolled in the study, we collected spot urine, an-
alyzed qualitatively and quantitatively UMOD protein,
measured creatinine, uric acid, sodium, potassium, cal-
cium, magnesium, phosphates, chlorides, and total pro-
tein concentrations and determined urine osmolality.
Qualitative protein analysis showed that UMOD was
reduced or absent in the patients’ urine. The same was
observed in urinary sediment. No abnormality in elec-
trophoretic mobility of residual UMOD protein was ob-
served in patients (Fig. 2).
To correlate individual analyte concentrations, we nor-
malized them to creatinine content and correlated re-
sulting values between affected individuals, nonaffected
individuals, and external controls. We found no statis-
tically significant (P > 0.05) changes in any of the pa-
rameters between healthy individuals and controls. In
contrast, except for phosphate, all the parameters were
significantly different in affected individuals compared
to controls (P < 0.05). Comparing the affected and un-
affected individuals within the family, significant reduc-
tion in excretion of urate, calcium, and UMOD were
found (Table 1). We next considered all the significantly
different parameters found between affected individuals
and controls, (Table 1) as disease status characteristics
Hodanˇova´ et al: Mapping of a new UAKD locus 1477
BE1 healthy individuals
BE1 patients
Controls
0
0
0.25
0.5
0.75
1
10 20 30 40
Individuals
Po
st
er
io
r p
ro
ba
bi
lity
50 60 70 80 90
Fig. 3. Posterior probabilities of having the
disease observed in 87 individuals. Gray sym-
bols represent, from left to right, DIV4, DIV6,
DIV5, DIII3, DII6, and DII5, respectively.
Black symbols represent, in the same order,
affected individuals DIV7, DIV3, DIII6, and
DIII4, respectively. Controls are represented
in white.
Table 2. Clinical and biochemical data used for individual’s status classification (individuals classified as affected are in bold)
Uric acid Ca2+ Uromodulin
Age Renal mmol/mmol mmol/mmol mmol/mmol Disease
Individuals year Anemia Hyperuricemia insufficiency creatinine creatinine creatinine probablity
DI1 Died at 68 Yes Yes Yes ND ND ND ND
DI3 Died at 50 NA yes ND ND ND ND
DII1 72 Yes Yes Transplantation at 60 ND ND ND ND
DII3 71 Yes Yes Yes ND ND ND ND
DII5 67 No No No 243 0.42 25.67 0.09
DII6 59 No No No 362 0.33 53.78 0.00
DIII1 Died at 37 Yes Yes Yes ND ND ND ND
DIII3 47 No No No 202 0.58 34.27 0.01
DIII4 44 Yes Yes Yes 17 0.05 0.00 1.00
DIII6 43 Yes Yes Yes 35 0.03 7.34 1.00
DIII9 41 No No No ND ND ND ND
DIV3 16 Yes Yes Yes 43 0.01 13.79 0.93
DIV4 14 No No No 283 0.49 28.05 0.00
DIV5 19 No No No 116 0.30 20.14 0.15
DIV6 17 No No No 128 0.13 19.66 0.22
DIV7 12 Yes Yes Yes 102 0.05 15.52 0.94
Controls(N = 77)
Average ± SD 36 ± 13 NA NA NA 246 ± 108 0.35 ± 0.25 35.23 ± 17.63 0,07 ± 0.15
Median 36 240 0.29 33.69 0.01
Range 22–18 90–990 0.04–7.50 7.71–110.97 0.00–0.95
Abbreviations are: ND, not determined; NA, not available.
and performed multivariate discriminant analysis. The
analysis revealed a highly significant discrimination be-
tween patients and controls (Wilks’ Lambda 0.68 approx-
imately F (8.72) = 4.15) (P < 0.0004). The variables con-
tributing the most to the discrimination were urine uric
acid/creatinine ratio (partial Wilks’ Lambda 0.91) (P <
0.01) and urine UMOD/creatinine ratio (partial Wilks’
Lambda 0.87) (P < 0.001). In order to classify each in-
dividual from family BE1, we used the resulting discrim-
inant function and based on equal priors we calculated
posterior probabilities that the individuals belong to the
disease or control group (Fig. 3). This analysis showed
that affected and unaffected individuals form separate
clusters and corroborated previous clinical observations
and biochemical investigations, which are summarized in
Table 2.
Immunohistochemical analysis
In control kidney tissue (Fig. 4A), UMOD was ex-
pressed strongly in the ascending limb of the loop of
Henle. The distribution was cytoplasmic; however, maxi-
mal staining intensity was seen on the apical membranes
of epithelial cells.
In kidney tissue from the FJHN patient with the
UMOD mutation (Fig. 4B), epithelium of the loop of
Henle displayed strong coarsely granular cytoplasmic
staining suggesting accumulation of UMOD in vesicular
compartment (i.e., endoplasmic reticulum).
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Fig. 4. Immunohistochemical analysis of uromodulin (UMOD) in kidney from control (A), familial juvenile hyperuricemic (FJHN) patient with
mutation in UMOD gene (B) and in affected individuals from families BE1 (C) and GB6 (D). Three different mechanism of UMOD dysfunction
associated with the uromodulin-associated kidney disease (UAKD) can be predicted. Massive UMOD storage along the secretory pathway (B),
strongly reduced expression of UMOD (C) and decreased and irregular UMOD staining on the background of interstitial fibrosis and tubular
atrophy (D).
In kidney tissue from patients from family BE1
(Fig. 4C), UMOD staining was significantly and uni-
formly reduced in the epithelium of the loop of Henle
in all three studied cases (DIII6, DIV3, and DIV7). Min-
imal signs of tubulointerstitial injury were observed.
In kidney from the patient from family GB6 (Fig. 4D),
decreased and irregular UMOD staining was observed
in tubules on the background of interstitial fibrosis and
tubular atrophy.
Positively stained tubular casts were seen occasionally
in control and patients samples except for the case with
the UMOD mutation.
Linkage analysis
Preliminary results from a two-point genome-wide
linkage analysis of 93 microsatellite markers in family
BE1 produced no conclusive proof of linkage; however,
one candidate region on chromosome 1, including mark-
ers D1S398 and D1S202 (LOD = 1.69) was identified for
further analysis. There were no other markers or regions
with LOD scores exceeding 1. For our candidate region,
we carried out fine mapping using 38 additional mark-
ers and obtained a maximum multipoint LOD score of
3.27 (Fig. 5). Haplotype analysis uncovered a single hap-
lotype segregating with the disease and recombination
events detected in affected individuals delimited the can-
didate region bound by markers D1S3470 and D1S1644
(Fig. 1). We then tested for linkage to the newly iden-
tified 1q41 locus in eight FJHN families from our pre-
vious studies, family C [23], families GB1, GB4, GB5,
GB6, GB9, GB10, and E2 [25], and MCKD family 6
[18], that did not show evidence of linkage to the al-
ready established FJHN/MCKD loci on chromosomes
16p11.2 and 1q21. All but one of the families produced
negative LOD scores within the entire candidate inter-
val. Families C, GB2, GB4, and GB5 had LOD scores <
−2 within the entire 1q41 interval, as well as the 16p11.2
interval, excluding linkage to those loci and thus provid-
ing evidence of further genetic heterogeneity in UAKD.
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Fig. 5. Multipoint overlapping logarithm of the odds (LOD) score analysis of the markers in the linked region on chromosome 1q41. The candidate
region in family BE1 is delimited by markers D1S3470 and D1S1644 based on recombination events in affected individuals. Note that using a less
stringent criterion of one LOD unit drop from the maximum (which includes also information from unaffected individuals), the candidate region
may be further restricted to D1S3470-D1S2857.
The single family with a positive LOD score within the
1q41 interval, family GB6, initially showed LOD = 0.6 at
markers D1S425, D1S2703, and D1S419. After genotyp-
ing additional markers, we found for this family a max-
imum LOD score of 2.07. Haplotype analysis demon-
strated in affected individuals a single haplotype, de-
limited by markers D1S237 and D1S2670, that segre-
gated with the disease phenotype. Both identified dis-
ease regions were, however, distinct and nonoverlapping
(Fig. 5). Because parallel immunohistochemical analysis
supported the possibility of genetically distinct origin of
the diseases (Fig. 4C and D), and since the LOD score
2.07 did not reach the generally accepted limit for deter-
mining linkage, we conclude that the segregation of the
candidate region haplotype on 1q41 with disease pheno-
type in family GB6 is likely to be a chance finding.
Candidate gene analysis
The critical region we have delimited in family BE1
spans 37.2 million bases, is fully sequenced, and con-
tains about 300 genes. Evaluating gene content, we have
selected and sequenced, in probands and healthy indi-
viduals from the family, nine candidate genes—ATPase,
H+ transporting, lysosomal 13 kD, V1 subunit G isoform
(3ATP6VIG3), feline leukemia virus subgroup C cellu-
lar receptor (FLVCR), hypothetical protein FLJ20605
(Unigene clusterHS.4932A), transforming growth fac-
tor beta 2 precursor (TGFb2), 5′-bisphosphate nucleoti-
dase 1(BPNT1), transmembrane 7 superfamily member
1 protein (TM7SF1), guanine nucleotide binding protein
(GNG4), and Jun dimerization protein p21 (SNFT). Al-
though several genetic variants were found in some of
the genes (data not shown), no “classic” deleterious mu-
tation was detected within the analyzed promoter regions,
exon/intron junctions, and coding sequences.
DISCUSSION
We describe here localization of a new UAKD locus
on chromosome1q41. We identified this locus by genome
scan and linkage analysis in a single family, which showed
the clinical and biochemical symptoms of UAKD and did
not show linkage to any of previously identified UAKD-
associated loci.
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Since the family size was not sufficient for the “affected
only” analysis, we focused first on detailed clinical and
biochemical characterization which would minimize the
possibility of disease status misclassification. Within the
family all the main signs of the disease, small kidney size,
anemia, hyperuricemia, elevated plasma creatinine and
hypouricuria, appeared at an early age, in probands DIV3
and DIV7 at the ages of 8 and 4 years old, respectively.
Renal insufficiency appeared in all affected individuals
in the third and fourth decades of life. The end stage re-
nal disease developed in the sixth to seventh decade of
life, which is relatively late compared to the typical cases
of FJHN. The early onset of biochemical signs and rela-
tively uniform clinical picture of the disease suggests that
it is not necessary to use age-based penetrance models in
subsequent linkage analysis. To assess the most current
biochemical status, we collected urines from available in-
dividuals (all individuals from the youngest generation)
and analyzed several biochemical parameters potentially
helpful in assessment of kidney function. Compared to
controls, in the patients we found significant changes in
excretion patterns of almost all of the tested biochem-
ical parameters. We used all these disease characteris-
tics in discriminant analysis, which calculated posterior
probabilities that the individuals belong to the disease
or healthy group. This analysis allowed us to classify and
confirm the affection status in the healthy individuals with
a very high degree of certainty.
The most significant biochemical changes observed in
patients were reduced excretion of urate, UMOD, and
calcium. Reduced excretion of urate, which is a key di-
agnostic marker of FJHN/MCKD, was not surprising.
Excretion patterns of UMOD observed in our study cor-
relate well with recent observation in patients with muta-
tions in the UMOD gene [36]. Our observation of reduced
UMOD excretion even in patients with no mutation in
UMOD gene is interesting. It suggests, that UMOD dys-
function plays a central role in UAKD development,
and implies that UAKD symptoms may result from var-
ious defects affecting UMOD transcription, translation,
posttranslational processing, cellular trafficking, GPI an-
choring, cell surface stability, and release. Three distinct
pathogenetic mechanisms leading to UMOD deficiency
can already be seen in immunohistochemical analysis
of kidney sections from patients with mutation in the
UMOD gene, probands from the family reported here,
and a proband from family GB6 (Fig. 4). Reasons for
low calcium excretions observed in the patients are not
clear. We can only hypothesize that through its calcium-
binding domains UMOD contributes to the regulation of
calcium metabolism. There are no data on urinary cal-
cium excretion in other FJHN/MCKD patients, and such
investigations are therefore warranted.
Having a high degree of certainty in the determination
of affection status, following the preliminary results of
genome scan, and analyzing 38 markers in 1q41 candi-
date locus, we observed in this family a statistically sig-
nificant evidence of linkage with a maximum multipoint
LOD score of 3.27. Analysis of the recombination events
in affected individuals uncovered a single haplotype seg-
regating with the disease and delimited candidate region
by markers D1S3470 and D1S1644. Unfortunately, we
were not able to confirm linkage to this candidate region
in eight additional FJHN families which did not map to
any of currently known FJHN/MCKD loci on 16p11.2
and 1q21. This result however does not lessen the prob-
ability or rule out the existence of the 1q41 candidate
region we have identified. The phenotype observed in
family BE1 is unusual among all the previously reported
FJHN/MCKD families in having precocious anemia, ab-
sence of gout, abnormalities in ions metabolism, different
pattern of UMOD expression in kidney biopsy, and rela-
tively late onset of renal insufficiency and therefore does
not match the typical criteria set for FJHN earlier [37].
This presentation is suggestive of a genetically distinct
origin of the disease in family BE1 and it is therefore
probable that the locus we have identified really repre-
sents a new UAKD locus which is distinct from that one
involved in previously investigated FJHN families.
The identified locus overlaps with three other kid-
ney related diseases, autosomal-dominant fibronectin
glomerulopathy [38], autosomal-recessive form of
steroid-resistant nephrotic syndrome [39], and pseudo-
hypoaldosteronism type II, [40], the phenotypes of which
are however distinct from the phenotype defined in fam-
ily BE1.
The critical region we have delimited is fully sequenced
and contains about 300 genes. In our gene content eval-
uation and candidate gene selection we first focused on
genes with prominent kidney expression. Applying sev-
eral bioinformatic approaches, we did not identify any
gene, the expression pattern of which would be kidney
and nephron segment-specific as is UMOD or genes caus-
ing other kidney specific diseases [34]. Second, we focused
on genes the defect of which may explain the observa-
tion of significantly reduced UMOD expression in kidney
biopsies. Since we had no tissue for in situ hybridization
analysis available, we considered two possibilities. First,
reduced UMOD expression may be caused by a mutation
in a transcription factor or hormone involved in UMOD
gene transcription activation. Atypical FJHN associated
with diabetes was found in a family with HNF1B mu-
tation [41], and a pathogenic mechanism linking HNF1B
mutation and FJHN symptoms was experimentally estab-
lished in mice in which the kidney-specific inactivation of
HNF1B led to greatly reduced UMOD expression [42].
A severe reduction in UMOD expression was also ob-
served in patients with hyperprostaglandin E syndrome
[43] and in two animal models, Brn1-deficient mouse [44]
and in hypothyroid rats [45].
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Second, reduced UMOD expression may be caused by
a mutation affecting a protein involved in posttransla-
tional modification or cellular traffic of UMOD. The im-
proper modification and/or mistargeting of UMOD may
then lead to a loss or masking of immunoreactive epitopes
and protein does not crossreact with available antibodies.
Considering both possibilities we selected and se-
quenced in a first round nine candidate genes. In all of
the selected genes no “classic” deleterious mutation was
detected within the promoter regions, exon/intron junc-
tions, and coding sequences. This finding, however, can
not completely rule out the involvement of those genes
in the disease development. The transcription of any of
those genes can be greatly affected by mutations in dis-
tant promoter regions or by intronic mutations affecting
mRNA processing. The cDNA studies, which would be
very useful in this respect, could not be performed, as we
did not have sufficient amounts of affected kidney tissues.
In addition to these analyzed genes, several transcrip-
tion factors, G protein regulators, protein kinases, ion
channels, and as yet uncharacterized proteins that may
be hypothetically involved in regulation of UMOD ex-
pression are located within the critical interval. Further
positional cloning efforts and efficient candidate gene se-
lection are, however, currently greatly hampered by the
size of delimited critical interval. Further progress de-
pends on identification of other families linked to the re-
gion proposed here. Our work provides a new “genomic
address” for such studies which may be performed in
FJHN/MCKD families in which genetic linkage has not
yet been demonstrated [11, 12, 22]. Positive results may
not only confirm and further narrow the identified 1q41
region but may also have direct diagnostic/clinical rele-
vance in affected families, enabling early treatment and
preventing the progression of the renal lesion [37].
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